Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82027 | 0.91 | SYK (0.37) | SYKNAMPTIDH1MAPK1BRD4 | |
| SCHEMBL84228 | 0.78 | NAMPT (0.35) | SYKNAMPTMAPK1MTOR | |
| SCHEMBL83679 | 0.77 | MTOR (0.41) | MAPK1MTOR | |
| SCHEMBL79935 | 0.76 | CSF1R (0.39) | NAMPTMAPK1JAK2 | |
| SCHEMBL5017322 | 0.72 | FLT3 (0.43) | NAMPTJAK2MTOR | |
| SCHEMBL82026 | 0.69 | MAPK1 (0.40) | MAPK1MTOR | |
| SCHEMBL83595 | 0.68 | PKM (0.40) | — | |
| SCHEMBL84227 | 0.68 | AGTR2 (0.33) | MTOR | |
| SCHEMBL81359 | 0.67 | FLT3 (0.45) | — | |
| SCHEMBL77343 | 0.67 | NPC1 (0.47) | MAPK1BRD4MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | SYK 446/4885NAMPT 265/4885IDH1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.